Phone: (707) 546-5553
Email Us
1140 Sonoma Avenue 1-A
Santa Rosa, CA 95405

News

HIFU: Prostate Cancer Treatment Has 97% Survival Rate

A prostate cancer treatment which is rarely offered on the NHS may give patients a 97% chance of survival after five years, a landmark study has suggested. The so-called “male lumpectomy” treatment works by treating just the prostate cancer tumor with High Intensity Focused Ultrasound (HIFU).

It is said to have “significantly fewer side effects” than traditional treatments and delivers high rates of cancer control. Prostate cancer is the most commonly diagnosed cancer in men, the second most common cause of cancer-related death in the US and the third most common cause in Europe. While already cleared by the US Food and Drug Administration (FDA), HIFU treatment is only available in very few centres in the NHS.

For more information about HIFU available in the U.S., to make an appointment call (707) 546-5553 or visit our at: www.californiahifu.com

Read the full story …

By | March 24th, 2016|HIFU, News|0 Comments

HIFU: Taking the UK By Storm

A treatment that uses sound waves to blast away prostate tumors has been proven to cure as many men of the disease as that of the surgery that removes the gland – while causing significantly fewer side effects. Until now the new procedure, called high-intensity focused ultrasound (HIFU), has been considered experimental.

This has meant that the majority of British men diagnosed with the condition – including former Rolling Stone Bill Wyman – have only been offered the more invasive operation called radical prostatectomy, which has a clear track record despite the risk of impotence and incontinence.

HIFU is a treatment that uses sound waves to blast away prostate tumours has been proven to cure as many men of the disease as surgery that removes the gland – while causing significantly fewer side effects. A landmark study announced at the European Association of Urology annual meeting in Munich revealed that focal HIFU, which targets only the tumour while preserving the healthy prostate tissue around it, offers a 93 per cent recurrence-free survival rate at five years, putting it on a par with prostatectomy.

Best-selling Author John Grisham Turns HIFU Advocate

John Grisham Turns Promoter for Focused Ultrasound (HIFU)

Takes a break from legal thrillers to tout HIFU’s benefits

Best-selling author John Grisham has a side job.

When the legal thriller writer is taking a break from stories of tort reform and multi-million dollar trials, or of small town justice gone awry and blackmailed jurors — or any of the other legal topics he’s covered in the roughly one book a year he’s written since 1988 — he thinks about high-intensity focused ultrasound.

Or rather, he’s busy raising money and awareness for the technology as part of the Focused Ultrasound Foundation, where he sits on the board. He “still doesn’t understand the technology” behind focused ultrasound, he said in a recent TEDx Talk in Charlottesville, Va., but nevertheless advocates for it because he’s found “no other cause, issue, non-profit, or charity that can potentially save so many lives.”

Grisham’s latest effort to get more eyes on, and more money for, the foundation is The Tumor: A Non-Legal Thriller, a 67-page book that tells the story of a man with glioblastoma. It includes diagrams of the procedure and pictures of an actual glioblastoma, and it’s available for free as an Amazon Single, where it was sitting at #16 on the most popular free Kindle Single list at the time of writing.

Read the full story here …

By | March 1st, 2016|Dr. Michael Lazar, News, Prostate Cancer|0 Comments

Study Supports Hemiablation HIFU for Prostate Cancer

High-intensity focused ultrasound (HIFU) hemiablation offers mid-term promising functional and oncologic outcomes in carefully selected patients with clinically localized prostate cancer (PCa), according to researchers.

In a prospective cohort study of 50 patients who underwent HIFU ablation of a single lobe of the prostate, the 5-year actuarial metastases-free survival, cancer-specific survival, and overall survival rates were 93%, 100%, and 87%, respectively, Roland van Velthoven, MD, and colleagues at the Jules Bordet Institute in Brussels, Belgium, reported in Prostate Cancer and Prostatic Diseases (2016;19:79-83).

The researchers documented complete continence (no pads) and erections sufficient for intercourse in 94% and 80% of patients, respectively.

“Our study suggests that hemiablation HIFU is a valid mini-invasive focal therapy strategy, feasible in day-to-day practice with satisfactory functional outcomes,” the investigators concluded.

The study included patients with localized PCa, a life expectancy of at least 5 years, and a prostate volume less than 40 cm3. The researchers used both multiparametric magnetic resonance imaging (MRI) and MRI-targeted biopsy to localize the tumor.

The cohort had a median follow-up of 39.5 months. The patients had a mean nadir PSA value of 1.6 ng/mL, a 72% reduction compared with initial PSA pre-treatment values. The median time to achieve PSA nadir was 3 months. Biochemical recurrence, according to the Phoenix definition (PSA nadir plus 2 ng/mL) and Stuttgart definition (nadir plus 1.2 ng/mL), occurred in 28% and 36% of patients, respectively.

The 5-year actuarial recurrence-free survival rates for patients with low- and intermediate-risk disease were 75% and 36%, respectively, according to the Phoenix definition and 58% and 27%, respectively, according to the Stuttgart definition.

Three patients showed a residual tumor in the treated lobe, and these were correctly treated with salvage radiation therapy.

The Press Democrat: Santa Rosa doctor one of few using new treatment for prostate cancer

Lazar is part of a vanguard of urologists who are treating prostate cancer with a newly approved procedure in the United States that uses ultrasound to zap cancerous tissue. The procedure, known as high-intensity focused ultrasound, or HIFU, is used in more than 30 countries around the world. Until this fall, it had not been cleared for use in the United States.

Lazar, who has traveled to Mexico six to eight times a year since 2007 to treat American men diagnosed with prostate cancer, is now one of a handful of doctors expanding use of the procedure in treatment centers in the United States.

“There’s been one case done in Louisville, one case done in San Francisco by me, and that’s it in the United States at this point, because it just got approved to where we can be sold the machines, get the machines set up and get the centers going,” Lazar said this week as he sat in his small Sonoma Avenue office.

Lazar, who has practiced in Santa Rosa since 1983, has been conducting the procedure using the Sonablate, a HIFU device manufactured by SonaCare Medical. The device is the first to win approval from the U.S. Food and Drug Administration, and since then a similar device made by a French competitor has also been cleared by the FDA.

Lazar said treating prostate cancer with HIFU has a number of advantages over radiation and surgery, including reducing the possibility of side effects such as erectile dysfunction and incontinence. Read the full article at The Press Democrat …

First Prostate Cancer Patient Treated with Minimally Invasive HIFU on West Coast

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center

November 18, 2015. San Francisco, CA – HIFU Prostate Services, LLC, a leading provider of minimally- invasive prostate cancer treatment, using High Intensity Focused Ultrasound (HIFU), announced that physician partner and Medical Director, Michael J. Lazar, MD treated the first prostate cancer patient in California with minimally invasive HIFU on November 18, in San Francisco at the San Francisco Surgery Center (SFSC). This will be the second patient ever treated in the country using Sonablate HIFU technology.

HIFU Prostate Services has partnered with Lazar and SFSC to establish a HIFU Center of Excellence where patients can receive the recently FDA-cleared Sonablate HIFU treatment. SFSC is located in downtown San Francisco, near Union Square, which offers patients a state-of-the-art facility in downtown that is convenient to hotels and the airport for men who will be traveling from around the country for this non-invasive treatment.

Lazar, who also serves as Medical Director of HIFU Prostate Services, has been working with HIFU since 2007, and was one of three physicians who proctored cases during clinical trials. Lazar will offer HIFU treatment to qualified patients and also provide medical guidance and serve as a proctor to physicians that are being trained on the Sonablate® HIFU system in San Francisco and surgery centers around the country.

Kevin Wienke, Administrator of the San Francisco Surgery Center states, “The Center is proud to be able to receive one of the first Sonablate® HIFU Systems in the country and to partner with Dr. Lazar and HIFU Prostate Services to offer our patients a viable option for prostate cancer.”

John W. Linn, chief executive officer of HIFU Prostate Services said, “The Sonablate® is the first device to receive regulatory authorization from the FDA for the ablation of prostate tissue. HIFU has been available in other countries for more than 10 years, but we are proud to be the first to make this game-changing technology available in the United States”.

Since 2004, approximately 4,000 U.S. men have been treated outside the U.S. where this technology is approved in over 30 countries. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence, which are typically reported with surgery and radiation.

Ken Hicks, a patient of Dr. Lazar’s who received HIFU treatment in 2007 in Puerto Vallarta, Mexico says, “Finally men in the U.S. can receive this innovative, minimally invasive therapy for their prostate cancers without traveling internationally. I still can’t believe I was eating dinner on the beach just hours after my HIFU procedure and I am doing great after 7 years. I highly recommend Dr. Lazar and HIFU to anyone who is eligible for this incredible procedure.”

About Dr. Michael Lazar

Lazar HIFU

A great medical partnership begins in San Francisco. Kevin Wienke (L), Administrator SF-SC and Dr. Michael Lazar (R), Director of HIFU Prostate Services.

Dr. Lazar is currently the Medical Director of HIFU Prostate Services (HPS) and clinical partner with HPS and SFSC with the HIFU program. He has been certified by the American Board of Urology four times and has practiced in Santa Rosa, Calif. since 1983. He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.

For more information on Dr. Lazar, visit www.californiahifu.com

About HIFU Prostate Services, LLC

HIFU Prostate Services (HPS) was founded in 2015 to provide men access to a less invasive treatment option for prostate disease focused on preserving quality of life. The mission of HPS is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS is lead by a seasoned management team with over 50 years of experience in the healthcare industry and over 30 years focused on HIFU technologies The company is headquartered in Charlotte, NC.

For additional information, visit www.hifuprostateservices.com.

By | November 18th, 2015|Dr. Michael Lazar, HIFU, News|0 Comments

Minimally Invasive Prostate Cancer Treatment HIFU Now Available in the U.S.

sonablate500After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence which are typically reported with surgery and radiation.

HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Newly appointed HPS Medical Director Michael J. Lazar, MD is set to provide medical guidance and proctoring to new physicians who will now be trained on the Sonacare® HIFU system in surgery centers around the country. Dr. Lazar has been treating patients with HIFU since 2007 and is one of only three U.S. physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials.

John W. Linn, chief executive officer of HPS commented, “I have known Dr. Lazar since 2007 and have been impressed with his patient care and dedication to the HIFU technology since his first treatment. He is the ideal medical director for HPS and for teaching this new technology to US physicians.”

Lazar will also operate his own HIFU Program in partnership with HPS, offering prostate treatments in downtown San Francisco near Union Square at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility that is convenient to hotels and the airport for patients interested in traveling from around the country for HIFU treatments. The actual Sonablate device has just been delivered to the Surgery Center in San Francisco, marking the first time ever that a HIFU device will be available at a medical center in the United States.

“It is very exciting to be a part of providing the vehicle for access to this technology for new and experienced HIFU users. Over the years, physicians in various stages of training have shown remarkable enthusiasm for providing HIFU for their prostate cancer patients, but they did not see a clear path for obtaining accessibility to the technology after FDA approval,” said Lazar. “HIFU Prostate Services takes the mystery and tedium out of the process by providing the highest quality of care, support and technology to the patient and to the urology community. Men who choose HIFU can contact HPS and then be referred to a regional HIFU surgeon. This approach facilitates wide availability of this treatment option for American men.”

HIFU offers patients a single, outpatient treatment for prostate cancer that is bloodless and allows men to return to their normal lifestyles within a few days. Although HIFU is designed as a single treatment, it can be repeated if needed. HIFU may also be used to treat patients that have failed radiation therapy and it does not preclude any future treatments including surgery or radiation.

About HIFU Prostate Services, LLC & Dr. Michael Lazar

At HIFU Prostate Services (HPS), our mission is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS was founded in 2015 by a seasoned management team with over 50 years of experience in the healthcare industry and over 30 years focused on HIFU technologies The company is headquartered in Charlotte, N.C.

lazar close up

Dr. Michael Lazar

Dr. Michael Lazar has been certified by the American Board of Urology four times and has practiced in Santa Rosa, California since 1983. He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.

For additional information, visit Dr. Michael Lazar at www.californiahifu.com, 707-546-5553 or www.hifuprostateservices.com. Media Contact: John Linn, 704-737-5925
.

HIFU Prostate Services Names Michael J. Lazar, MD Medical Director

Nov. 4, 2015 — HIFU Prostate Services (HPS) has named Dr. Michael Lazar as HPS Medical Director. As HPS Medical Director Dr. Lazar will provide medical guidance and proctoring to new physicians that are being trained on the Sonablate® HIFU system in surgery centers around the country. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence, which are typically reported with surgery and radiation. Lazar has been treating with HIFU since 2007 and is one of three US physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials.

Dr. Lazar will operate his own HIFU Program, in partnership with HPS, offering prostate treatments in downtown San Francisco, near Union Square, at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility in downtown that is convenient to hotels and the airport for patients interested in traveling from around the country for this recently FDA-cleared treatment.

By | November 11th, 2015|Dr. Michael Lazar, HIFU, News|0 Comments

North Bay Business Journal article on Dr. Michael Lazar — HIFU: poised for approval by FDA

Click to view full story from North Bay Business Journal …. A nonsurgical, outpatient treatment for prostate cancer, with a low rate of side effects, is poised for approval by the U.S. Food and Drug Administration within the next few weeks.  Treatment with high-intensity focused ultrasound (HIFU) waves use heat focused at a specific location to destroy the area of the prostate gland affected with cancer, while any tissue outside of the focal point remains unharmed.  “The oncological results for HIFU are broadly comparable to radical surgery or radiation but the side effects are less,” said Dr. Michael Lazar, a urology specialist in Santa Rosa.  HIFU is most effective for patients with early stage prostate cancer where the cancer is localized to the prostate. The procedure preserves healthy tissue and preserving nerves, urine flow and erectile function in about 80 percent of cases compared to 40 percent–50 percent with surgery or radiation.  HIFU is also performed on an out-patient basis, taking one to four hours. A urinary catheter is inserted after the procedure and must be kept in place for one to three weeks. The most common side effects are infections in the prostate area, and incontinence, to a lesser degree than other therapies.  Click to view full story from North Bay Business Journal ….

High Intensity Focused Ultrasound (HIFU) Therapy is Gaining International Acceptance for the Treatment of Medical Conditions

your-questions-answeredA growing number of international medical organizations have already adopted High Intensity Focused Ultrasound (HIFU) therapy for treating an increasing number of conditions, and as a viable option to traditional invasive surgery, according to Dr. Michael Lazar, a Santa Rosa, California-based Urologist and a leading advocate for HIFU as an effective treatment for prostate cancer.

Dr. Lazar states, “The scientific community has known for years that high heat kills cancer. But only in recent years has the science advanced to the point where focused ultrasound energy can be used to provide pinpoint accuracy, sparing healthy tissue and preserving nerves, urine flow and erectile function in a majority of cases compared with traditional procedures, while also delivering the required amount of heat needed to destroy, or ablate, cancer.”

Today HIFU is being deployed around the world, especially in Europe, for the treatment of abdominal kidney tumors, urological cancers, uterine fibroids, and to relieve neuropathic pain associated with bone cancer, in addition to being a non-invasive treatment for prostate cancer. Medical literature also reports the use of HIFU in treating liver, breast and brain tumors as well as other conditions.”

For example, according to the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) located in Vienna, Austria, positive results were achieved with transcranial Magnetic Resonance MR-guided focused ultrasound surgery (tcMRgFUS) as a non-invasive treatment of essential tremors, neuropathic pain and Parkinson’s disease. CIRSE also reports that there have also been some investigations into the use of HIFU for temporarily opening the blood-brain barrier, allowing absorption of drugs into the brain.

Furthermore, a minimally invasive catheter-based HIFU system — designed to ablate heart tissue responsible for atrial fibrillation — has been approved for use in Europe and is undergoing an FDA approved trial in the United States.

“Adoption of HIFU has proceeded at a faster rate among international medical communities than in the United States, however, there are hopeful signs that this technique will soon be available to a broader range of patients here at home so they will not have to travel to hospitals outside of the U.S. to take advantage of this procedure,” Dr. Lazar said.

For more information about Dr. Michael Lazar, go to the HIFU website or call (707) 546-5553. His office is located at 1140 Sonoma Ave #1A, in Santa Rosa, CA 95405.

Indianapolis, Indiana-based SonaCare Medical LLC, a leading developer of minimally-invasive HIFU technology, is bringing several HIFU systems to market to meet growing global demand. SonaCare Medical, LLC, serves customers around the world through its family of affiliate companies including: USHIFU, International HIFU and Focus Surgery. For additional information, go to: www.sonacaremedical.com.